Aditxt, Inc. Update: Nasdaq Delisting Notice

If you follow Aditxt, Inc. (ticker: ADTX), you need to know about a major change to the company’s status on the Nasdaq stock exchange. Here is the situation.

1. What happened?

The Nasdaq Hearings Panel has denied Aditxt’s request to remain on the exchange. Trading of Aditxt stock is scheduled to stop when the market opens on June 25, 2026. Following this, Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission to officially remove the company from the exchange.

2. Why did it happen?

Aditxt failed to meet two fundamental Nasdaq requirements:

• The Price Rule: Nasdaq requires stocks to maintain a price above $1.00 per share. Aditxt was unable to sustain this, even after executing seven reverse stock splits intended to artificially boost the share price.
• The Equity Rule: Companies must maintain at least $2.5 million in stockholders' equity. Aditxt reported a significant deficit, with negative equity exceeding $35 million—well below the required threshold.

3. The "Last-Ditch" Plan

Interim CEO Jeffrey Busch proposed a plan to sell the company’s revenue-generating subsidiary, Ignite Proteomics, to a Special Purpose Acquisition Company (SPAC) for $150 million. The company argued this would resolve their equity deficit and stabilize their finances.

Why it failed: The Nasdaq panel was skeptical of the valuation. Aditxt had acquired Ignite Proteomics for approximately $35 million only months prior, and the panel questioned how the asset’s value could have jumped to $150 million in such a short window. Furthermore, the market did not respond positively to the announcement, and the share price failed to recover. Given that the remainder of the business generates no revenue and loses roughly $5 million every quarter, the panel concluded that the plan was insufficient to ensure long-term stability.

4. Who is affected?

• Investors: Shareholders will lose the liquidity and strict oversight provided by a major exchange. ADTX shares will likely move to the "Over-the-Counter" (OTC) markets, often called "pink sheets." These markets typically have lower trading volume, wider price gaps between buyers and sellers, and fewer reporting requirements than Nasdaq.
• The Company: Aditxt loses the prestige and visibility of a major exchange listing. This makes it significantly harder to raise capital, as many institutional investors are prohibited from holding or trading OTC stocks.

5. What should you do?

• Check your brokerage: Contact your broker to see how they handle stocks that move to the OTC market. Many platforms restrict trading these stocks, which could prevent you from selling your shares through your current account.
• Manage your expectations: Delisting is a clear indicator of severe financial distress. Focus on the company’s actual financial health—specifically its negative equity and ongoing quarterly losses—rather than speculative recovery narratives.
• Stay cautious: Delisted stocks are often highly volatile and difficult to sell. The lack of required transparency in the OTC market makes it significantly harder to track the company’s performance or hold management accountable.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute professional investment advice. Always conduct your own due diligence before making investment decisions.